FORT LAUDERDALE, Fla., March 07, 2017 -- Securities Arbitration and Investment Litigation Lawyers with multiple law firms are investigating customer claims against Raymond James, Morgan Stanley and BofA Merrill Lynch (and others) for their recommendations and solicitations of Linn Energy LLC limited liability company interests to retail customers, including in a May 2015 securities offering.
Investors in Linn Energy have been financially devastated by Linn Energy’s bankruptcy filing and may have legal claims to recover their losses as against the brokerage firms that recommended the investment.
The securities arbitration and investment litigation lawyers at the Ciklin Lubitz Law Firm, The Law Firm of David R. Chase, P.A., and Silver Law Group are investigating Raymond James, Morgan Stanley and RBC Capital Markets, among others, as to the suitability and appropriateness of their investment recommendations of Linn Energy to their customers.
If you purchased Linn Energy, or other oil and gas stock, based upon the recommendation of your stock broker or financial advisor, you may contact us to discuss your potential case and legal rights.
For a free and confidential consultation call: 1-800-856-3352
or visit: www.oilgasinvestmentfraudlawyer.com. No recovery, no attorneys’ fees.


Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 



